Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors.

In conclusion, the present study revealed that TP53 and PIK3CA may be appropriate biomarkers to screen for patients who would benefit most from ICIs, which could guide precise immunotherapy for patients with TNBC. PMID: 32218835 [PubMed - as supplied by publisher]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research